Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Announces Special Stockholder Meeting
17 janv. 2025 17h24 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Further Strengthens Financial Position Through Sale of Excess Capital Equipment for $17 Million
07 janv. 2025 09h00 HE | Lifecore Biomedical, Inc.
Company Believes it is Well Positioned for Mid-Term and Long-Term Growth asCurrent Capacity Continues to Support up to $300 Million in Annual Revenue CHASKA, Minn., Jan. 07, 2025 (GLOBE NEWSWIRE)...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Participate at 43rd Annual J.P. Morgan Healthcare Conference
06 janv. 2025 16h05 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Reports Second Quarter Fiscal 2025 Financial Results and Provides Corporate Update
02 janv. 2025 16h05 HE | Lifecore Biomedical, Inc.
-- Recorded Revenues of $32.6 Million for Q2 Fiscal 2025 -- -- Signed Multiple Development Agreements with New Customers -- -- Strengthened Balance Sheet with Financing Raising Approximately $24.3...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Report Financial Results for Second Quarter of Fiscal 2025 on January 2, 2025
19 déc. 2024 16h05 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Selected by Nirsum Labs to Provide CDMO Services Supporting Clinical Development of Innovative Opioid Use Disorder Treatment
19 déc. 2024 07h00 HE | Lifecore Biomedical, Inc.
Development Services Span Tech Transfer, Process Assessment and Method Validation for Fill and Finish of NRS-033 for Planned Phase 2 Trial Lifecore to Leverage Differentiated Capabilities and...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Amends and Extends Revolving Credit Facility with BMO
26 nov. 2024 16h05 HE | Lifecore Biomedical, Inc.
Three-Year Term Extension Combined with Simplification and Reduction of Interest Rates Helps Further Strengthen Company’s Balance Sheet and Overall Financial Position Builds Upon Other Recent...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical Hosts Virtual Investor Day
21 nov. 2024 16h17 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Present at Stephens Annual Investment Conference
12 nov. 2024 16h05 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...
Lifecore-Corporate_Logo_2C.png
Lifecore Biomedical to Host Virtual Investor Day Prior to Market Open on November 21, 2024
07 nov. 2024 07h00 HE | Lifecore Biomedical, Inc.
CHASKA, Minn., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today...